BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

5656 related articles for article (PubMed ID: 306870)

  • 21. Recall skin-test antigens and the prognosis of stage I melanoma.
    Aranha GV; McKhann CF; Simmons RL; Grage TB
    J Surg Oncol; 1979; 11(1):13-6. PubMed ID: 431077
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BCG in cancer therapy: theoretical bases of immunotherapy.
    Dodd MJ
    Am J Nurs; 1979 Feb; 79(2):310-4. PubMed ID: 311587
    [No Abstract]   [Full Text] [Related]  

  • 23. Delayed cutaneous hypersensitivity ad peripheral blood lymphocyte counts in gastrointestinal cancer.
    Gupta S; Seth SK; Udupa KN; Sen PC
    Ann Acad Med Singap; 1980 Jan; 9(1):71-6. PubMed ID: 7447383
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunocompetence, immunodeficiency and prognosis in cancer.
    Hersh EM; Gutterman JU; Mavligit GM; Mountain CW; McBride CM; Brugess MA; Lurie PM; Zelen M; Takita H; Vincent RG
    Ann N Y Acad Sci; 1976; 276():386-406. PubMed ID: 800324
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunoprofile studies for patients with bronchogenic carcinoma. I. Correlation of pretherapy studies with survival.
    Liebler GA; Concannon JP; Magovern GJ; Dalbow MH; Hodgson SE
    J Thorac Cardiovasc Surg; 1977 Oct; 74(4):506-18. PubMed ID: 302883
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BCG stimulation of immune responsiveness in patients with malignant melanoma. Preliminary report.
    Gutterman J; Mavligit G; McBride C; Frei E; Hersh EM
    Cancer; 1973 Aug; 32(2):321-7. PubMed ID: 4722915
    [No Abstract]   [Full Text] [Related]  

  • 27. In vivo and in vitro observation of cellular immune parameters in squamous cell carcinoma of the oral cavity and its correlation with tumor load and prognosis.
    Das SN; Khanna NN; Khanna S
    Cancer Invest; 1986; 4(3):207-16. PubMed ID: 3719410
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Immunological reactions of skin melanoma patients to nonspecific and adaptive immunotherapy].
    Trapeznikov NN; Iavorskiĭ VV; Kadagidze ZG; Malaev SG; Kupin VI
    Vopr Onkol; 1977; 23(8):27-33. PubMed ID: 906404
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of BCG (Tice strain) on primary sensitization to 2,4-dinitrochlorobenzene and on established delayed hypersensitivity in human malignant melanoma.
    Mavligit GM; Gutterman JU; Hersh EM
    J Natl Cancer Inst; 1976 Oct; 57(4):749-51. PubMed ID: 1003526
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunohistological analysis of peptide-induced delayed-type hypersensitivity in advanced melanoma patients treated with melanoma antigen-pulsed mature monocyte-derived dendritic cell vaccination.
    Nakai N; Katoh N; Germeraad WT; Kishida T; Ueda E; Takenaka H; Mazda O; Kishimoto S
    J Dermatol Sci; 2009 Jan; 53(1):40-7. PubMed ID: 18804963
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunotherapy for melanoma.
    Vaisrub S
    JAMA; 1973 Sep; 225(10):1242. PubMed ID: 4542440
    [No Abstract]   [Full Text] [Related]  

  • 32. Clinical studies of methanol extraction residue fraction of Bacillus Calmette-Guérin as an immunostimulant in patients with advanced cancer.
    Moertel CG; Ritts RE; Schutt AJ; Hahn RG
    Cancer Res; 1975 Nov; 35(11 Pt 1):3075-83. PubMed ID: 1102082
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Decrease in immunoreactivity in melanoma. Analysis of DNCB tests in the literature].
    Remy W; Dorn R; Ulm K; Mayerhausen W
    Z Hautkr; 1986 Dec; 61(24):1767-77. PubMed ID: 3825218
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cell-mediated immune competence in patients with prostatic carcinoma.
    Stefani SS; Menon M; Canning JR; Clark SS
    J Urol; 1978 Oct; 120(4):431-4. PubMed ID: 702665
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A multiparametric observation of immune competence in breast cancer and its correlation with tumour load and prognosis.
    Das SN; Khanna NN; Khanna S
    Ann Acad Med Singap; 1985 Apr; 14(2):374-81. PubMed ID: 3876055
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vivo and in vitro assays of immunocompetence in bronchogenic carcinoma.
    Alsabti EA
    Oncology; 1979; 36(4):171-5. PubMed ID: 157453
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients.
    Escobar A; López M; Serrano A; Ramirez M; Pérez C; Aguirre A; González R; Alfaro J; Larrondo M; Fodor M; Ferrada C; Salazar-Onfray F
    Clin Exp Immunol; 2005 Dec; 142(3):555-68. PubMed ID: 16297169
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Immunologic response in patients with melanoma of the skin].
    Mutsenietse AIa; Volrat AA; Popena BA; Bumbieris IaV; Shapovalova EA
    Vopr Onkol; 1983; 29(4):34-8. PubMed ID: 6858048
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selective immunological evaluation of mycosis fungoides.
    Cooperrider PA; Roenigk HH
    Arch Dermatol; 1978 Feb; 114(2):207-12. PubMed ID: 629547
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunologic defects in melanoma patients: lack of effect of BCG therapy.
    Gersten MJ; Hadden EM; Kaplan MH; Pinsky CM; Armstrong D; Hadden JW
    Clin Bull; 1977; 7(2):63-9. PubMed ID: 902403
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 283.